The massive potential dilution (up to 80M shares at $0.15) is the key risk — watch for the stockholder vote on the exchange cap waiver and any early conversion notices from SOD. The Nasdaq compliance cure is a near-term positive, but the stock will trade on whether the AHA channel and pseudohypoxia test generate real revenue, which is entirely unsecured and years away. Monitor the next 10-Q for actual equity classification and any early conversion activity.
Price Chart
Executive Summary
Vivos Therapeutics closed the acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test, issuing $12M in Series C Convertible Preferred Stock (convertible at $0.15/share into up to 80M common shares). The deal is expected to add >$10M to stockholders' equity, potentially curing a Nasdaq minimum equity deficiency, but creates massive potential dilution (up to ~238% of current shares outstanding) and all revenue projections are contingent on unsecured future agreements and clinical validation.
Key Financial Metrics
Key Facts
- Vivos issued 12,000 shares of Series C Convertible Preferred Stock with an aggregate stated value of $12,000,000 to SOD Sciences.
- Vivos acquired 3,057,879 shares of SOD common stock (11% fully diluted equity) and a 50% undivided co-ownership interest in the pseudohypoxia early-warning test and related IP.
- No cash consideration was paid by either party.
- Series C Preferred is convertible at $0.15/share into up to 80,000,000 shares of Vivos common stock, subject to a 19.99% exchange cap (6,718,517 shares) pending stockholder approval and a 4.99% beneficial ownership limitation.
- Vivos expects the transaction to increase stockholders' equity by more than $10 million, potentially curing the Nasdaq minimum stockholders' equity deficiency ($2.5M requirement).
- Pro forma stockholders' equity as of June 30, 2026 is approximately $6.6 million.
- The conversion price of $0.15 represented a premium to the closing price on the signing date.
- Vivos obtained consent from Streeterville Capital, LLC (holder of Series B Preferred) for the issuance.
- All potential revenue from the AHA channel (325,000+ patients) and the pseudohypoxia test is subject to negotiation of definitive agreements, clinical validation, regulatory clearance, and bankruptcy court approval for AHA.
Financial Impact
Expected increase in stockholders' equity of more than $10 million (stated as $10,380,000 in press release). Pro forma equity of ~$6.6M as of June 30, 2026. Potential dilution of up to 80M shares (238% of 33.6M shares outstanding) if full conversion occurs after stockholder approval.
Risk Factors
- Massive potential dilution: Series C Preferred is convertible into up to 80M shares (238% of current 33.6M outstanding), though capped at 19.99% until stockholder approval.
- All revenue projections are contingent: AHA channel requires definitive agreements and bankruptcy court approval; pseudohypoxia test needs clinical validation and regulatory clearance.
- Nasdaq compliance is not assured: the company warns that if it does not evidence compliance at its next periodic report, it may be subject to delisting.
- The preferred stock classification in permanent equity is subject to auditor and Nasdaq review — any reclassification could reverse the equity cure.
- SOD's test has no established revenue or clinical validation — the entire strategic thesis is speculative.
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-047601 |
| Exhibit: ex10-4.htm | 0001493152-26-047601 |
| Exhibit: ex3-1.htm | 0001493152-26-047601 |
| Exhibit: ex99-1.htm | 0001493152-26-047601 |
| Exhibit: ex10-2.htm | 0001493152-26-047601 |
| Exhibit: ex10-3.htm | 0001493152-26-047601 |
| Document: 0001493152-26-047601-index-headers.html | 0001493152-26-047601 |
| Document: 0001493152-26-047601-index.html | 0001493152-26-047601 |
| Document: 0001493152-26-047601.txt | 0001493152-26-047601 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1313 (−2.52%) |
Oct 19, 2026 7d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1313 (−6.88%) |
Oct 19, 2026 7d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1313 (−6.61%) |
Oct 15, 2026 11d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1313 (−8.05%) |
Oct 15, 2026 11d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1313 (−8.05%) |
Sep 30, 2026 25d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1313 (+11.88%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1313 (−41.62%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1313 (−52.57%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1313 (+56.41%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1313 (−61.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers